SEC filing · 8-K

NRX Pharmaceuticals, Inc.: Material agreement

NRx Pharmaceuticals subsidiary was awarded a prime contract of up to approximately $11.2 million from DARPA.

Filed October 5, 2026

Positive for the company

What happened

On September 29, 2026, subsidiary NRx Defense Systems entered into a prime contract with DARPA to conduct the SPARC-TMS clinical trial.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to NRX Pharmaceuticals, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.